Literature DB >> 20697856

Absence of gain-of-function JAK1 and JAK3 mutations in adult T cell leukemia/lymphoma.

T Kameda1, K Shide, H K Shimoda, T Hidaka, Y Kubuki, K Katayose, Y Taniguchi, M Sekine, A Kamiunntenn, K Maeda, K Nagata, T Matsunaga, K Shimoda.   

Abstract

Janus kinase 1 (JAK1) and JAK3 plays a critical role in lymphocyte proliferation and differentiation. Somatic JAK1 mutations are found in 18% of adult precursor T acute lymphoblastic leukemias and somatic JAK3 mutations are found in 3.3% of cutaneous T cell lymphomas. Some of the mutations are confirmed as a gain-of-function mutation and are assumed to be involved in leukemogenesis. Adult T cell leukemia/lymphoma (ATLL) is a type of T cell neoplasm, and activation of JAK/STAT pathways is sometimes observed in them. We investigated JAK1 and JAK3 mutations in 20 ATLL patients. No JAK1 mutations were found, and five types of single nucleotide polymorphisms were observed in 12 cases, whose frequencies almost match those in Asian populations. As for JAK3, a synonymous mutation was found in one case. JAK1 and JAK3 mutations are unlikely involved in the leukemogenesis of ATLL.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20697856     DOI: 10.1007/s12185-010-0653-2

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  41 in total

1.  Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses.

Authors:  S J Rodig; M A Meraz; J M White; P A Lampe; J K Riley; C D Arthur; K L King; K C Sheehan; L Yin; D Pennica; E M Johnson; R D Schreiber
Journal:  Cell       Date:  1998-05-01       Impact factor: 41.582

2.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

3.  Evidence for aberrant activation of the interleukin-2 autocrine loop by HTLV-1-encoded p40x and T3/Ti complex triggering.

Authors:  M Maruyama; H Shibuya; H Harada; M Hatakeyama; M Seiki; T Fujita; J Inoue; M Yoshida; T Taniguchi
Journal:  Cell       Date:  1987-01-30       Impact factor: 41.582

Review 4.  Inactivation of tumor suppressor genes and the progression of adult T-cell leukemia-lymphoma.

Authors:  Y Yamada; S Kamihira
Journal:  Leuk Lymphoma       Date:  2005-11

Review 5.  Janus kinases in immune cell signaling.

Authors:  Kamran Ghoreschi; Arian Laurence; John J O'Shea
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

6.  Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID.

Authors:  S M Russell; J A Johnston; M Noguchi; M Kawamura; C M Bacon; M Friedmann; M Berg; D W McVicar; B A Witthuhn; O Silvennoinen
Journal:  Science       Date:  1994-11-11       Impact factor: 47.728

7.  Down-regulation of SHP1 and up-regulation of negative regulators of JAK/STAT signaling in HTLV-1 transformed cell lines and freshly transformed human peripheral blood CD4+ T-cells.

Authors:  Jihua Cheng; Dongsheng Zhang; Changhong Zhou; Wayne A Marasco
Journal:  Leuk Res       Date:  2004-01       Impact factor: 3.156

8.  Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers.

Authors:  Eun Goo Jeong; Min Sung Kim; Hyo Kyung Nam; Chang Ki Min; Seok Lee; Yeun Jun Chung; Nam Jin Yoo; Sug Hyung Lee
Journal:  Clin Cancer Res       Date:  2008-06-15       Impact factor: 12.531

9.  Loss-of-function JAK3 mutations in TMD and AMKL of Down syndrome.

Authors:  Serena De Vita; Claire Mulligan; Suzanne McElwaine; Franca Dagna-Bricarelli; Monica Spinelli; Giuseppe Basso; Dean Nizetic; Jürgen Groet
Journal:  Br J Haematol       Date:  2007-05       Impact factor: 6.998

10.  Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia.

Authors:  Elisabetta Flex; Valentina Petrangeli; Lorenzo Stella; Sabina Chiaretti; Tekla Hornakova; Laurent Knoops; Cristina Ariola; Valentina Fodale; Emmanuelle Clappier; Francesca Paoloni; Simone Martinelli; Alessandra Fragale; Massimo Sanchez; Simona Tavolaro; Monica Messina; Giovanni Cazzaniga; Andrea Camera; Giovanni Pizzolo; Assunta Tornesello; Marco Vignetti; Angela Battistini; Hélène Cavé; Bruce D Gelb; Jean-Christophe Renauld; Andrea Biondi; Stefan N Constantinescu; Robin Foà; Marco Tartaglia
Journal:  J Exp Med       Date:  2008-03-24       Impact factor: 14.307

View more
  6 in total

1.  Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia.

Authors:  D Bellanger; V Jacquemin; M Chopin; G Pierron; O A Bernard; J Ghysdael; M-H Stern
Journal:  Leukemia       Date:  2013-09-19       Impact factor: 11.528

Review 2.  The promise of Janus kinase inhibitors in the treatment of hematological malignancies.

Authors:  Emilee Senkevitch; Scott Durum
Journal:  Cytokine       Date:  2016-10-27       Impact factor: 3.861

3.  JAK2 V617F Mutation in Adult T Cell Leukemia-Lymphoma.

Authors:  Hossein Ayatollahi; Mohammad Hadi Sadeghian; Mohammad Reza Keramati; Ehsan Ghayoor Karimiani; Amir Hossein Jafarian; Abbas Shirdel; Hossein Rahimi; Mohammad Esmaeel Zangane-Far; Arezoo Shajiei; Maryam Sheikhi
Journal:  Indian J Hematol Blood Transfus       Date:  2015-12-17       Impact factor: 0.900

4.  FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma.

Authors:  Natalina E Elliott; Susan M Cleveland; Victor Grann; John Janik; Thomas A Waldmann; Utpal P Davé
Journal:  Blood       Date:  2011-08-05       Impact factor: 22.113

Review 5.  Disease-specific mutations in mature lymphoid neoplasms: recent advances.

Authors:  Mamiko Sakata-Yanagimoto; Terukazu Enami; Yasuhisa Yokoyama; Shigeru Chiba
Journal:  Cancer Sci       Date:  2014-05-12       Impact factor: 6.716

Review 6.  Safety and Danger Considerations of Novel Treatments for Atopic Dermatitis in Context of Primary Cutaneous Lymphomas.

Authors:  Karol Kołkowski; Magdalena Trzeciak; Małgorzata Sokołowska-Wojdyło
Journal:  Int J Mol Sci       Date:  2021-12-13       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.